Dr. Matthew L. Meyerson

Dr. Matthew L. Meyerson, MD, PhD, is an internationally recognized physician–scientist specializing in cancer genomics and molecular oncology. He serves as Professor of Pathology at Harvard Medical School, Director of Cancer Genomics at the Dana-Farber Cancer Institute, and is a member of the Broad Institute of MIT and Harvard. Dr. Meyerson earned his medical degree from Harvard Medical School and his PhD in biology from Harvard University. He completed his residency in pathology at Massachusetts General Hospital and pursued fellowship training at the Whitehead Institute. He is board-certified in Pathology and is widely acknowledged for his pioneering work in cancer genetics and precision medicine.

Dr. Meyerson’s research has centered on the discovery of genetic alterations driving cancer development and progression, with landmark contributions in lung cancer genomics. He was instrumental in identifying EGFR mutations and other oncogenic drivers that have shaped targeted therapy strategies for lung adenocarcinoma. His laboratory has also led projects in cancer genome sequencing and structural genomics, contributing to The Cancer Genome Atlas and international collaborations. He has authored hundreds of peer-reviewed publications that have fundamentally advanced understanding of the molecular basis of cancer and informed clinical practice in precision oncology.

In addition to his scientific and clinical leadership, Dr. Meyerson is a dedicated educator and mentor. He has trained numerous physician–scientists who have become leaders in oncology and genomics research. He serves on editorial boards, advisory panels, and national committees guiding the future of cancer research and genomic medicine. Through his groundbreaking discoveries, collaborative leadership, and commitment to mentorship, Dr. Matthew Meyerson continues to shape the field of cancer genomics and expand the possibilities of precision oncology worldwide.